Volume 2.44 | Nov 19

Immune Regulation News 2.44, November 19, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Dietary Intervention in Infancy and Later Signs of Beta-Cell Autoimmunity   ShareThis
Early exposure to complex dietary proteins may increase the risk of beta-cell autoimmunity and type I diabetes in children with genetic susceptibility. Researchers tested the hypothesis that supplementing breast milk with highly hydrolyzed milk formula would decrease the cumulative incidence of diabetes-associated autoantibodies in such children. [N Engl J Med]

Read the Review  
Stress-Free Isolation of Highly Purified Mouse CD4+ T Cells
with EasySep®
 
 
READ THE REVIEW STEMCELL Technologies Inc
 


SPECIAL FEATURE

Interested in recruiting talented individuals? Post your career opportunities in Immune Regulation News at no cost. Contact us at [email protected]

Follow us on Twitter! @Immune_News


SCIENCE NEWS

Inovio Pharmaceuticals’ HIV DNA Vaccine Achieves Strong T Cell Immune Responses in Phase I Human Trial
Inovio Pharmaceuticals, Inc. announced that it has achieved high vaccine-induced response rates and a strong magnitude of immune responses in its Phase I clinical study of PENNVAX(TM)-B, a DNA vaccine for the prevention of HIV infection. [Inovio Pharmaceuticals, Inc. Press Release]

It Takes a Village: Mechanism Alerts Neighbors to Amplify Immune Response
New research reveals a clever strategy that enables a host organism to outsmart an invading bacterium by counteracting its efforts to suppress the innate immune response. [Press release from Science Daily discussing online prepublication in Immunity]

Discovery in How HIV Thwarts the Body’s Natural Defense Opens Up New Target for Drug Therapies
The study, marks the “beginning of a fascinating story that will shed new light on an important but still poorly understood aspect of the interaction of HIV with natural killer cells,” according to an editorial in the journal. [Press release from EurekAlert! discussing online prepublication in Cell Host & Microbe]

Request A Poster  
Isolate Untouched Cells for
Antigen Processing and Presentation
with EasySep®
 
 
REQUEST A POSTER STEMCELL Technologies Inc
 


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

Regulated Expression of Nuclear Receptor ROR(Gamma)t Confers Distinct Functional Fates to NK Cell Receptor-Expressing ROR(Gamma)t+ Innate Lymphocytes
By using adoptive transfer of genetically tagged lymphoid tissue inducer-like cells, researchers demonstrate that natural killer cell receptors (NKR)-ROR(gamma)t+ innate lymphocytes but not natural killer cells were direct progenitors to NKR+ROR(gamma)t+ cells in vivo. [Immunity]

Endothelial Heparan Sulfate Controls Chemokine Presentation in Recruitment of Lymphocytes and Dendritic Cells to Lymph Nodes
The in vivo function of endothelial heparan sulfate in lymphocyte homing and stimulation of the immune response has not been elucidated. Here, researchers generated mutant mice deficient in the enzyme Ext1, which is required for heparan sulfate synthesis, in a Tek-dependent and inducible manner. [Immunity]

STAT6 Transcription Factor Is a Facilitator of the Nuclear Receptor PPAR(Gamma)-Regulated Gene Expression in Macrophages and Dendritic Cells
Researchers demonstrate a mechanism describing how inflammatory molecules modulate peroxisome proliferator-activated receptor gamma signaling in distinct subsets of cells. [Immunity]

MicroRNAs Prevent the Generation of Autoreactive Antibodies
Here, researchers have examined the role of microRNAs in terminal B cell differentiation by analyzing Cd19-Cre(ki/+)Dicer1(fl/fl) mice. They found that in the absence of Dicer, the transitional and marginal zone B cell compartments were overrepresented and follicular B cell generation was impaired. [Immunity]

Hes1 Is a Critical but Context-Dependent Mediator of Canonical Notch Signaling in Lymphocyte Development and Transformation
Researchers showed that conditional inactivation of Hes1, a well-characterized Notch target gene, in adult murine bone marrow cells severely impaired T cell development without affecting other Notch-dependent hematopoietic lineages such as marginal zone B cells. [Immunity]

Cell-Cell Propagation of NF-(Kappa)B Transcription Factor and MAP Kinase Activation Amplifies Innate Immunity Against Bacterial Infection
Here, researchers report a host mechanism of cell-cell communication that circumvents the effector proteins and strongly amplifies IL-8 expression during bacterial infection. [Immunity]

Degranulation of Natural Killer Cells Following Interaction with HIV-1-Infected Cells Is Hindered by Downmodulation of NTB-A by Vpu
Researchers show that triggering the natural killer (NK) cell coactivation receptor NK-T- and -B cell antigen (NTB-A) alongside NKG2D promotes NK cell degranulation. [Cell Host Microbe]

PD-L1 Blockade Effectively Restores Strong Graft-Versus-Leukemia Effects without Graft-Versus-Host-Disease After Delayed Adoptive Transfer of T Cell Receptor Gene-Engineered Allogeneic CD8+ T Cells
Researchers investigated whether the use of MHC-mismatched T cells would prolong the in vivo persistence of tumor-reactive T cell receptor gene expressing T cells by continuous antigen-driven proliferation via the endogenous potentially alloreactive receptor. [Blood]

Constitutive Reductions in mTOR Alter Cell Size, Immune Cell Development, and Antibody Production
Because mTOR knock-outs are embryonic lethal, researchers generated a viable hypomorphic mouse by neo-insertion that partially disrupts mTOR transcription and creates a potential physiologic model of mTORC1/TORC2 inhibition. [Blood]

Indoleamine 2,3-Dioxygenase Specific, Cytotoxic T Cells as Immune Regulators
Here, researchers describe that spontaneous cytotoxic T-cell reactivity against indoleamine 2,3-dioxygenase (IDO) exists not only in cancer patients but also in healthy individuals. They show that the presence of such IDO-specific CD8+ T cells boosted T cell immunity against viral or tumor-associated antigens by eliminating IDO+ suppressive cells. [Blood]

Paradoxical Effects of Constitutive Human IL-32(Gamma) in Transgenic Mice During Experimental Colitis
Here, researchers investigated the role of IL-32 in intestinal inflammation by generating a transgenic mouse expressing human IL-32(gamma). [Proc Natl Acad Sci USA]


INDUSTRY NEWS

Jefferson Awarded Multi-Million Dollar NIH Grant to Create a Center of Excellence for Autoimmune Diseases
The Department of Neurology at Jefferson Medical College of Thomas Jefferson University has been awarded a multi-million dollar grant from the National Institutes of Health (NIH) for the creation of a center of excellence to study autoimmune diseases from basic science research to its translation into clinical applications. [Thomas Jefferson University Hospital Press Release]

Immunovaccine Inc. Announces Phase I/II Clinical Plan for DPX-Survivac to Target Ovarian Cancer
Immunovaccine Inc. announced that it will focus the Phase I/II clinical development plan for DPX-Survivac on ovarian cancer. [Immunovaccine Inc. Press Release]

Athersys Announces FDA Authorization of Phase II Clinical Trial for Inflammatory Bowel Disease With Pfizer Regenerative Medicine
Athersys, Inc. announced that the U.S. Food and Drug Administration (FDA) has authorized commencement of a Phase II clinical trial evaluating the safety and efficacy of administration of MultiStem(R), Athersys’ allogeneic investigational cell therapy product, for the potential treatment of ulcerative colitis. [Athersys, Inc. Press Release]

BioSante Pharmaceuticals Sells Oncolytic Virus Technology to Cold Genesys, Inc.
BioSante Pharmaceuticals, Inc. announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. [BioSante Pharmaceuticals, Inc. Press Release]

Another Key Patent Granted in the U.S.
Lophius Biosciences announced that the USTPO has granted the U.S. Patent US 78293318 entitled “Use of urea-adjuvanted polypeptides for diagnosis, prophylaxis and therapy”. [Lophius Biosciences Press Release]

Prostate Cancer Drug Gets Lukewarm Review
There is only “moderate”‘ evidence that the newly approved prostate cancer drug Provenge helps patients, according to an analysis done for Medicare that was made public. [The New York Times]


POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)


EVENTS (Listed by Date)

American Association for Cancer Research (AACR) Tumor Immunology – Basic and Clinical Advances
November 30-December 3, 2010
Miami, United States

Vaccines Europe 2010
December 1-2, 2010
London, United Kingdom

Cell Symposia: Influenza – Translating Basic Insights
December 2-4, 2010
Washington, D.C., United States

5th Annual Stem Cell Meeting on the Mesa
December 7, 2010
La Jolla, United States

NEW  Safety Symposium organized by the NIH RAC and Co-hosted by CliniGene: Retroviral and Lentiviral Vectors for Long-Term Gene Correction: Clinical Challenges in Vector and Trial Design
December 9-10, 2010
Bethesda, United States

The 50th Midwinter Conference of Immunologists at Asilomar
January 22-25, 2011
Pacific Grove, United States

Phacilitate 7th Annual Cell & Gene Therapy Forum 2011
January 24-26, 2011
Washington, D.C., United States

Phacilitate 9th Annual North American Vaccine Forum
January 24-26, 2011
Washington, D.C., United States

AACR-ACS Joint Meeting on Chemistry in Cancer Research: The Biological Chemistry of Inflammation as a Cause of Cancer
January 30-February 2, 2011
San Diego, United States

Keystone Symposia: Dendritic Cells and the Initiation of Adaptive Immunity
February 12-17, 2011
Santa Fe, United States

Keystone Symposia: Genetics, Immunology and Repair in Multiple Sclerosis
February 15-20, 2011
Taos, United States

Lorne Infection and Immunity Conference 2011
February 16-18, 2011
Lorne, Australia

18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
February 27-March 2, 2011
Boston, United States

The 6th International Conference on Oncolytic Viruses as Cancer Therapeutics
March 16-19, 2011
Las Vegas, United States

2011 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting
March 18-22, 2011
San Francisco, United States

Microbiota and Mucosal Immunology: The Interface in Health and Disease
April 14-16, 2011
San Francisco, United States

GTCbio 2nd International Conference on Cancer Immunotherapy & Immunomonitoring
May 2-5, 2011
Budapest, Hungary

American Society of Gene and Cell Therapy (ASGCT) 14th Annual Meeting
May 18-22, 2011
Seattle, United States

Gordon Research Conference: Viruses & Cells
May 29-June 3, 2011
Lucca (Barga), Italy

NEW  DNA Vaccines 2011
July 12-14, 2011
San Diego, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES

Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)


Product Manager – Pluripotent Stem Cells (STEMCELL Technologies)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.

Visit here to post your career opportunities.



Have we missed an important article or publication in Immune Regulation News? Click here to submit!




Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Immune Regulation News: Archives  |  Events  |  Subscribe  |  Contact Us